Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc.
U.S. Court of Appeals for the Federal Circuit
Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc.
Opinion
Case: 23-1395 Document: 61 Page: 1 Filed: 07/09/2024
NOTE: This order is nonprecedential.
United States Court of Appeals for the Federal Circuit ______________________
REGENERON PHARMACEUTICALS, INC., Appellant
v.
MYLAN PHARMACEUTICALS INC., CELLTRION, INC., APOTEX INC., Appellees ______________________
2023-1395, 2023-1396 ______________________
Appeals from the United States Patent and Trademark Office, Patent Trial and Appeal Board in Nos. IPR2021- 00880, IPR2021-00881, IPR2022-00257, IPR2022-00258, IPR2022-00298, IPR2022-00301. ______________________ ORDER The parties, having so agreed, IT IS ORDERED THAT: The above-captioned appeals are dismissed under Fed. R. App. P. 42(b) with each side to bear their own costs.
FOR THE COURT
July 9, 2024 Date
ISSUED AS A MANDATE: July 9, 2024
Reference
- Status
- Unpublished